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Visceral Leishmaniasis (VL) caused by protozoan parasite Leishmania is a vector 
borne disease and infection is limited not to human but also to animals worldwide. For 
infection identification and prevalence in both Leishmania endemic and nonendemic 
regions, several serological and genetic techniques are used. Although diagnostic 
techniques and clinical symptoms can establish illness status, it is extremely difficult 
to diagnose infection in the absence of symptoms. Asymptomatic are healthy people 
who have an infection but are unaware of it. The epidemiology of asymptomatic 
Leishmaniasis is critical for its eradication. Only a small percentage of infected people 
are clinically suspected of having VL, as the majority of them may not show any 
symptoms and remain asymptomatic. Some asymptomatic infections may go away 
after a while, or they may linger for years, or they may develop to illness with clinical 
signs. Asymptomatic infection varies per endemic location, but almost all of them 
point to this hidden category of parasite infection. It is now critical to understand 
many factors such as diagnostic markers, genetic markers, and immunological mark-
ers along with different risk factors. All of these criteria, as well as some innovative 
techniques to diagnosing and controlling asymptomatic leishmaniasis, will be covered 
in this chapter. The main focus will be on asymptomatic condition of Indian Visceral 
Leishmaniasis, which is caused by Leishmania donovani and spreads via female sand 
fly P. argentipes biting. The numerous criteria that play a role in asymptomatic to 
symptomatic conversion in a specific time period will also be discussed in this chapter.
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1. Introduction
Leishmaniasis is a serious public health problem in many countries throughout 
the world. The illness is caused by numerous intracellular protozoan parasites of 
the genus Leishmania. The most frequent vectors of this neglected infectious illness 
are phlebotomine sandflies, Phlebotomus and Lutzomyia, which is most widespread 
in the tropics and subtropics of Africa, Asia, America, and southern Europe. This 
illness is the world’s second most lethal parasitic killer (after malaria). It’s multi-
faceted. It can be a deadly murderer in certain forms, or a merciless mutilator who 
disfigures its victims for life in others. There are now an estimated 12 million cases 
of leishmaniasis in 98 countries, with 1.5–2 million new cases emerging annually, 
1–1.5 million instances of cutaneous leishmaniasis, and 5,00,000 cases of visceral 
leishmaniasis (VL). VL can create large-scale epidemics with a high case fatality 
rate. VL (kala-azar) is a latent danger to more than 147 million people residing in 
the disease-endemic South East Asia region of the Indian subcontinent, which is 
Leishmania - One of the Most Diverse Anthroponotic Parasitic Diseases
2
caused by Leishmania donovani. Out of the five VL-affected nations in the area 
(India, Bangladesh, Nepal, Thailand, and Bhutan), India accounts for more than 
80% of recorded cases, while Bhutan and Thailand have sporadic reports. Bihar is 
the most VL-endemic state in India, accounting for 90 percent of all VL cases in the 
country [1]. L. infantum, L. chagasi, or Leishmania donovani are the parasites that 
cause Visceral Leishmaniasis (VL) in North Africa and Southern Europe as well as 
Latin America and East Africa respectively [2]. The transmission of L. donovani is 
usually thought to be anthroponomic. Its prevalence is gradually growing around 
the world, creating a public health issue in the VL endemic zone. The classic WHO 
definition of Visceral Leishmaniasis is “a person with clinical symptoms (primarily 
persistent irregular fever, splenomegaly and weight loss) and serological and/or 
parasitological evidence.” Leishmaniasis Post Kala Azar (PKDL) has been related to 
Visceral Leishmaniasis (VL). According to WHO, probable PKDL affects individu-
als from VL endemic areas who have numerous hypopigmented maculae, papules, 
plaques, or nodules but no corresponding loss of sensitivity. However, these are 
the circumstances in which Leishmania infection manifests as symptoms. Many 
people in endemic locations are infected with the parasite yet show no symptoms of 
the sickness, according to previous research. These are classified as asymptomatic 
stages of Leishmania infection. L. donovani infection can range from asymptomatic 
carrier to full-blown symptomatic illness with persistent fever, splenomegaly, pan-
cytopenia, and hypergammaglobulinemia. Visceral leishmaniasis has an asymptom-
atic incubation period of variable duration [3]. A large majority of those who have 
been exposed to the parasite are asymptomatic, with just a tiny number of people 
exhibiting clinical manifestations [4, 5]. A disease is considered asymptomatic if 
it lacks the visible symptoms that are normally associated with it. Asymptomatic 
conditions may not be detected unless medical tests are performed. Importantly, 
doctors lack the tools necessary to tell apart asymptomatic patients from those who 
are suffering from something more subtle [6]. In a Mexican cutaneous leishmaniasis 
region in 1953, the term asymptomatic in Leishmania infection was first used [7]. 
Asymptomatic Leishmania infection was used initially in 1974 by Pampiglione but 
the description has remained ambiguous five decades later. At this time, there is no 
way of knowing who of the asymptomatically infected persons would acquire VL 
illness and when. Asymptomatic people are those who live in an endemic region 
and have an immune response to Leishmania (either antibodies or a particular 
cellular response), or who have parasites—or parasite DNA—in their blood, but 
are otherwise healthy [8]. Escalating asymptomatic leishmaniasis due to distinct 
Leishmania species like L. donovani and L. infantum is critical for determining 
trends in the disease’s prevalence. This first interaction between parasite and host is 
known as infection. The parasite can be killed by inherent or acquired immunity in 
the host, or it might persist by using an effective mechanism that bypasses the host’s 
defenses. If the parasite persists, it may lead to a fascinating dynamic interaction 
between the host and parasite, where the host becomes an asymptomatic carrier 
when everything is in balance. Due to co-evolution, it is quite frequent in several 
parasite illnesses for the number of patients to be less when compared to the vast 
number of persons with asymptomatic infection (in general, an infected person 
who is asymptomatic is not necessarily a patient). Because of this, asymptomatic 
instances of VL are common in regions with the disease [9, 10].
2. Epidemiology
It is essential to understand the global prevalence of asymptomatic leishmani-
asis. In addition, it’s critical to look at the variables that contribute to asymptomatic 
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infection. The variation arises because of changes in parasite virulence and 
host demographic characteristics, as well as from research designs and the tests 
employed to determine asymptomatic infection. Worldwide epidemiological sta-
tistics show that asymptomatic VL can come from both endemic and non-endemic 
areas. Those who are infected may unintentionally transfer the disease to others. 
They may go away on their own, or they may develop symptoms at a later time. 
As per some findings Asymptomatic infections are those who remain seropositive 
for many (up to 10–12) years without developing into active disease [11, 12], and 
are more prevalent in VL endemic regions [13]. In the New World, asymptomatic 
leishmaniasis was considerably more frequent than in the Old World. The higher 
prevalence might be explained by the greater diversity of leishmaniasis in the New 
World as a result of the vector’s adoption of new hosts and climate change [14]. 
Asymptomatic leishmaniasis was less common in children than in the general 
population. This difference, however, was insignificant on a statistical basis. It was 
hypothesized that the rise in infection prevalence with age was owing to young chil-
dren’s reduced exposure to infectious sandfly bites [15]. Some indicators indicate 
that in VL endemic locations, the ratio of asymptomatic vs. active VL patients  
varies: 2.4:1 in Sudan, 4:1 in Kenya, 5.6:1 in Ethiopia, between 4:1 and 17:1 in the 
Indian subcontinent, and 50:1 in Spain [16]. Reports from the other endemic 
regions also confirm the existence of parasitic DNA in all VL causing species in 
asymptomatic individuals.
According to a meta-analysis of original articles reporting asymptomatic 
leishmaniasis, the prevalence of asymptomatic leishmaniasis was 11.3%, 95% 
confidence interval (CI) 8.6%–14.4%] in general population, 36.7% [95% CI 
27.6%–46.8%] in inhabitants living in the same or neighboring household to the 
symptomatic patients, and 11.8% [95% CI 7.1–19%] in HIV infected patient. 
Meta-regression analysis also showed no significant change in the prevalence of 
asymptomatic leishmaniasis during the last 40 years [17]. From 1982 to 2015, the 
trend of total leishmaniasis’ asymptomatic proportion did not change considerably, 
according to the meta-regression study [coefficient = 0.0350 (95% CI, −0.0213 to 
0.0913), P = 0.2233] [17]. But, while the disease’s geographical range is broad, it 
is not continuous. The study also suggest, for L. donovani, the pattern of asymp-
tomatic infection has not altered over time [coefficient = 0.0015 (95 CI, −0.0531 
to 0.0561), P = 0.9564]. In contrast, the frequency of asymptomatic L. infantum 
infection has grown with time, although this shift is statistically insignificant 
[coefficient = 0.0824 (95 percent CI, −0.0126 to 0.1774), P = 0.0892]. According 
to research on L. infantum in the New World, the prevalence has considerably 
grown over time [coefficient = 0.0908 (95% CI, 0.0321 to 0.1496), P = 0.002]. 
The frequency of asymptomatic leishmaniasis in children is also rising over time 
[coefficient = 0.0599 (95% CI, 0.0066 to 0.1133), P = 0.028]. Drought, hunger, and 
high population density all contribute to the spread of the illness. The infection-
to-disease ratio varies from village to village and also changes over time within 
the same community [18]. Asymptomatic incident L. donovani infection is nine 
times more common than incident VL illness in VL high-endemic foci in India and 
Nepal [19]. Within the next 18 months, around 1 in 50 of new yet latent infections 
developed into VL. There is one important asymptomatic category comprises those 
individuals of endemic regions who turn seronegative in due course of time [19]. 
These people most likely acquire the required level of immune response following 
parasite exposure, which protects them from future illness development by effi-
ciently removing living parasites. They are most likely not carrying live parasites 
and can be called real resistant instances. The spontaneous change of seropositive 
to seronegative status ranges from 33–86% [19–22]. However, a research conducted 
in Bangladesh found that this conversion rate drops to as low as 6.3% after a year 
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among those with high antibody titers [23]. These people give more tangible proof 
that a threshold immune response level is required to protect the host against 
parasites. Despite the fact that the majority of seropositive asymptomatic people go 
on to become seronegative, these individuals are known to contribute to the spread 
of disease outside of endemic areas [24, 25].
3. Diagnosis
Diagnosis of VL is done by serological tests and molecular test along with 
direct parasite identification technique. Direct techniques are Leishmania parasite 
isolation from spleen, bone marrow, or blood for microscopy or culture. Different 
serological tests are ELISA, direct agglutination test (DAT), immunofluorescence 
antibody test (IFAT), indirect immunofluorescence (IIF), western blot (WB), rK39 
immuno-chromatographic strip test while molecular tests include polymerase chain 
reaction (PCR), qRT-PCR and k-DNA southern blot whereas immunological test 
include Montenegro Skin Test (MST)/Leishmania skin test (LST) or Interferon 
Gamma Release Assay (IGRA). The lack of a good biomarker makes defining 
Leishmania asymptomatic infections extremely difficult. It’s also unclear how to 
distinguish parasite persistence in an asymptomatically infected person from new 
infections that develop after the first episode, i.e. old parasites eliminated by the 
immune response followed by new infectious parasite populations that would fol-
low the same destiny. Asymptomatic infections cannot be diagnosed with a single, 
widely approved test. It cannot be diagnosed using any standard or commercially 
available methods. Patients who are infected with Leishmania do not show any 
symptoms, but tests such as the polymerase chain reaction (PCR) or leishmania 
skin test (LST)/Montenegro skin test (MST) are positive regardless of whether 
they show any symptoms [22]. Population-based demographic and immunological 
surveys showed high but variable prevalence of leishmanial antibodies in the popu-
lation of Bihar [26]. Serological test DAT/ELISA can perform in epidemiological 
studies as is noninvasive. But is indirect methodology and tells antibody response 
due to Leishmania infection. Because of the varying durations between infection 
and seroconversion (ranging from 3 months to 7 years), serology may not be a use-
ful predictor of infection when employed in cross-sectional research [19]. The most 
often used techniques include an intradermal skin test that indicates the cellular 
immune response associated with prior exposure to Leishmania and the identifica-
tion of anti-Leishmania antibodies, a less specific indication of infection or con-
tinuing illness [27]. Conventional PCR is direct tool as show presence of Leishmania 
specific DNA in interest of samples (blood, buccal swab, urine). Sensitivity and 
specificity vary for selection of primers. These above mentioned techniques are in 
use worldwide in epidemiological study to know prevalence of Leishmania infection 
in healthy individuals. But when data compare is compare with active Leishmania 
cases tough to distinguish healthy infection, i.e. asymptomatic. Using DAT sero-
conversion as a measure of infection, studies found that asymptomatic infection 
was nine times more common than acute VL illness in high-endemic foci in Bihar 
[19]. However, in any longitudinal epidemiological investigation, seroconversion 
should be the primary criteria for detecting asymptomatic infection. The variation 
in the ratio of VL cases versus asymptomatic cases in different L. donovani and L. 
infantum endemic areas from 2.4:1 in Sudan to 50:1 in Spain [28] reflects variations 
in parasite virulence and host features, However, this may also be due to variations 
in research design and the methodologies used to diagnose asymptomatic infection. 
Cell immunity generally lasts for several years, and in some cases, for the rest of a 
person’s life [29, 30]. Serological indicators, on the other hand, can go from positive 
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to negative in as little as four months after the initial sample is examined [22]. In 
endemic locations where mean parasitemia levels are low or intermittent, serology 
is generally unreliable for identifying silent Leishmania infection [6]. Cytokine 
release assays are useful for detecting asymptomatic individuals among immu-
nocompetent subjects in VL-endemic areas; they can also detect the same among 
immunosuppressed subjects following solid organ transplantation [31]. When 
compared with the reference test SLA-lymphoproliferative assay, IL-2 appears as a 
new, 100% sensitive and specific marker for asymptomatic individuals with a posi-
tive cellular response (compared with 100% and 84.78%, respectively, for IFN-γ) 
[32]. Some laboratory tests, including SLA-stimulated PBMC assay, may be difficult 
to perform under certain conditions. In contrast, the WBA holds much promise 
as a test at the point-of-care level [33]. The WHO recently recommended screen-
ing healthy populations for leishmaniasis infection using SLA-stimulated blood. 
There are ways to diagnose those who have asymptomatic Leishmania infection by 
whole blood stimulation with the soluble Leishmania antigen (SLA), followed by 
plasma cytokine and chemokine measurements. Combining these diagnostic tests 
with molecular studies might assist in estimating the real scope of the Leishmania 
outbreak in the endemic region. CXCL10 and CXCL9 DPS were shown to be reliable 
indicators for identifying asymptomatic individuals in L. infantum and L. donovani 
endemic regions. In distant areas, it makes samples more accessible and reduces the 
cost of epidemiological and epidemic investigations [34].
The immunological determinants such as Adenosine deaminase (ADA), 
Interferon gamma (IFN-γ), Tumor Necrosis Factor alpha (TNF-α) and Interleukin 
10 (IL-10) were examined to predict probable biomarkers for conversion to symp-
tomatic VL. Asymptomatic cases were also earlier reported to harbor the parasite 
in their blood [35, 36]. Many immunological methods such as direct agglutination 
test (DAT) and lateral flow immune-chromatographic tests, such as rK39 and 
rkE-16 have been introduced to screen large number of individuals in endemic areas 
[37–39]. Leishmania infantum/chagasi infection is endemic in Sicily. Approximately 
47% of residents live in areas at risk of infection. The prevalence of asymptomatic 
carriers is unknown. In asymptomatic subjects, IFAT showed sensitivity (30.1%) 
higher than rK39-ELISA (26.3%) for the detection of cryptic infection, even though 
a lower specificity was reported (63.4 vs. 76.3%) .
Molecular methods are the most suited due to the lack of a gold standard and the 
limitations of conventional diagnostic procedures, where parasitology is ethically 
impractical for persons without symptoms and serological tests do not discriminate 
between past and present illness. Recent molecular methods, such as conventional 
polymerase chain reaction (PCR) and quantitative real time PCR assay (qPCR), 
have made considerable advances in screening, diagnosis, and post-therapy follow-
up, allowing for better sensitivity than prior serological assays. Quantitative PCR 
(qPCR) is now a days promising tool for detection and quantification of Leishmania 
and able to describe threshold as well as reference value for asymptomatic infection.
There are several types of molecular methodologies, and the choice of use should 
be based on what results are expected to be achieved. While in the conventional 
Polymerase Chain Reaction (cPCR) the results are only qualitative, quantitative  
products can be obtained in the Real-Time technique (qPCR), such as the levels of 
parasitic DNA circulating in the blood [40]. The sensitivity of the assays may vary 
according to the types of targets and samples used. The most used amplification tar-
gets are: kinetoplast DNA (kDNA) [41, 42], internal non-coding spacer region (ITS-1) 
[43] and the smaller ribosomal subunits (SSU - rRNA) [44–46]. Sudarshan et al. [35] 
when performing a qPCR, analyzed the level of circulating parasites to differentiate 
a possible disease progression. They obtained a minimum level of detection of 0.001 
parasitic genomes/mL of blood and 34.79% of positive samples by the technique, 
Leishmania - One of the Most Diverse Anthroponotic Parasitic Diseases
6
using the kDNA and hydrolysis probes of the TaqMan type, as a target and method of 
visualizing the products. Likewise, Kaushal et al. [6, 47] (S. Das et al., 2014; Kaushalet 
al., 2017, [6, 47] (S. Das et al., 2014; Kaushal et al., 2017) (Das et al. 2014, Kaushal et al. 
2017, ([6, 47], when carrying out a study to detect asymptomatic individuals, obtained 
an amount < 5 parasites/mL of blood and a positive sample rate of 21.54%, using 
kDNA as a target and SYBR Green I as a result detection system. Sudarshan et al.  
[48], affirm that Leishmania DNA may be used as a marker of infection since it is 
detected before the seroconversion of antibodies. Individuals can be diagnosed as 
seronegative when they are tested before the development of immunity or when it is in 
a very low quantity, not being identified by serological methods. Similar data were also 
suggested by Costa et al. [27] and Bhattarai et al. [49], wherein asymptomatic infec-
tions detected by molecular methods have been observed in seronegative people. This 
demonstrates that possibly due to the limitations of serological methods, molecular 
tests are more suitable for the identification of asymptomatic cases. Although parasitic 
DNA is considered the first infection marker before immunological conversion [35], 
there are controversies regarding its use. The limitation of the use of DNA as a target is 
found in a possible detection of the genetic material of the parasite when it is already 
dead, although this is discussed, the half-life of the nucleic acid in the body is around 
24 hours, which can cause flaws in distinguishing viable parasites from detecting 
fragments of lifeless parasites. Lack of standardization of a methodology still becomes 
a gap that can lead mainly to problems and delays in detection of the cases. Moreover, 
the use of nanoparticle techniques represents a trend for diagnosis, immunotherapy, 
and programs to eliminate VL. These methodologies bring a new approach with new 
forms of diagnosis and drugs, where improvements in efficacy and less toxicity can be 
observed. There will be continuous and significant improvements to all their current 
roles in diagnostics and will also provide multiple roles in terms of recognizing other 
DNA or materials, using fluorophores or other active molecules. it is reasonable to have 
a lower value of serum hemoglobin, hematocrit, and albumin among symptomatic 
patients. So, they would be considered as a marker of symptomatic diseases rather 
than a risk or protective factor. Studies are going on to define asymptomatic as yet 
there is no or very less agreement between different markers. Although Gold standard 
for Leishmaniasis detection is parasitological confirmation by microscopy which need 
splenic aspirate. But for asymptomatics it is not possible as ethical issues are very high 
because of invasive nature of samples. As the use of spleen or bone marrow aspirate is 
not ethical in asymptomatic subjects, the negative predictive value (NPV) cannot be 
exactly evaluated.
4. Immunology
Asymptomatic cases differ considerably from VL patients, and it is assumed 
that a mixed profile is crucial not only for the management of parasite replica-
tion but also for the preservation of these people’ immune state. The increased 
number of cells expressing different cytokines demonstrates this. However, in 
VL-endemic areas, the clinical form is frequently asymptomatic, followed by pro-
tective immunity with a predominant type 1 T-cell response [50]. Asymptomatic 
seemed to have mixed profile having an increase of IFN-γ + neutrophils/eosino-
phils and NK cells, of IL-12+ eosinophils/monocytes, along with increase of IL-4+ 
neutrophils and NK cells and IL-10+ eosinophils/monocytes [51]. Despite earlier 
findings of a constant type 1 T-lymphocyte immune response during asymp-
tomatic VL it was recently shown that asymptomatic patients’ PBMC generated 
significant amounts of IL-10 when stimulated with L. infantum recombinant 
antigens [52].
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Different findings point to the idea that IL-10 is a key immunomodulator in 
asymptomatic people, dampening host defense mechanisms and favoring immune 
response regulation following parasite elimination. Furthermore, CD4+ T cells 
from asymptomatic patients infected with L. infantum have been shown to generate 
significant amounts of IL-5 [53]. In immunocompetent people, leishmania infection 
is typically asymptomatic, although the percentage of HIV+ people infected with 
the parasite who stay asymptomatic is unknown. HIV+ individuals might still have 
a Th1-type cellular response to Leishmania despite their weakened immune system. 
These people may be identified using cytokine release tests, which identify IFN-γ in 
the supernatants of SLA-stimulated PBMC and IFN-γ and IL-2 in SLA-stimulated 
whole blood. These biomarkers appear to be 100% reliable for detecting asymp-
tomatic immune responders to Leishmania among HIV+ patients [33]. Analyses of 
cytokine responses in symptomatic and asymptomatic VL patients’ peripheral blood 
mononuclear cells (PBMCs) indicated that the production of Th17 cytokines was 
highly linked with the asymptomatic status [54, 55]. It was discovered by Carvalho 
et al. that peripheral blood mononuclear cells (PBMCs) from people with subclini-
cal or asymptomatic infection (positive serology and skin test for Leishmania 
antigen) react to stimulation with Leishmania antigen by producing IL-2, IFN- and 
IL-12 [50]. An Indian study found that active disease elicited a mixed IFN-/IL-10 
response, but asymptomatic infections (IFN- release assay [IGRA]–positive endemic 
healthy controls) did not trigger an antigen-driven whole-blood IL-10 response [56]. 
Surprisingly, the frequency of CD4+ T cells is higher in people with asymptomatic 
infections who have positive LST [57], Furthermore high levels of IFN- are produced 
by CD8+ T cells isolated from asymptomatic patients, which implies that CD8+ cells 
play a role in human resistance to Leishmania infection. Furthermore, researchers 
discovered that in asymptomatic people, a distinct subpopulation of CD4+ cells that 
produced both IFN- and IL-5 was important for infection management [22, 53]. A 
longitudinal study conducted in Sudan recently suggested that Th17 cells may play 
a protective role in human VL, and it was found that L. donovani stimulates the 
production of IL-17 and IL-22 by exposed PBMCs from healthy and resistant sub-
jects who did not develop VL before or after cytokine response testing. In addition, 
elevated levels of IFN-γ, C reactive protein, nitric oxide, and IL-12 in the blood have 
also been reported to offer resistance in asymptomatic patients [58]. Disease resistant 
endemic individuals have an immune response that shields them against pathogenesis 
in response to an insect bite which are quite similar to those of VL immunology, and 
as a result, they cannot be utilized to provide a clear picture of protective immune 
parameters in asymptomatic patients. Besides the protective immune response, it 
appears that these people either possess a large number of long-lived memory B cells 
that continuously secrete antibodies or they are continually exposed to Leishmania 
but do not acquire VL as a result of the protective immunological response [59]. The 
quantity of antibodies in blood has been connected to the incidence of asymptomatic 
to symptomatic VL conversion. Although it will be difficult to track these instances, 
they may aid in the discovery of host immunological mechanisms that influence dis-
ease susceptibility and resistance. Strong cell mediated immunity, a broad repertoire 
of memory T and B cells, and short-lived plasma cells may be linked with the immune 
biology of resistant asymptomatic infections (they do not show seropositivity for a 
longer period). Focused research on these people might disclose the characteristics 
of protective immunity that are needed to build a preventive vaccination candidate. 
In asymptomatic patients, the levels of ADA, IL-10, and IFN-γ were continuously 
high, with ADA and IL-10, but not IFN-γ, remaining higher as clinical symptoms 
progressed into active VL. ADA and IL-10 might be used as a biomarker in the transi-
tion from asymptomatic to symptomatic VL [60]. Due to their high innate cellular 
immunity, many asymptomatic individuals become seronegative without acquiring 
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VL. IFN- γ became high in asymptomatic infection but dropped after conversion, but 
TNF-α levels did not alter much at either stage of illness. The cytokine profile might 
be utilized to better treat VL patients with autoimmune diseases, as well as to identify 
and protect individuals with asymptomatic infection who are at risk of developing 
illness. Assays for cytokine release are already being utilized to detect asymptomatic 
individuals [31, 61]. Cytokines, which operate on macrophages, are receiving a lot 
of attention these days because of their ability to alter the immune response. Studies 
on the function of cytokines in asymptomatic infections and/or subclinical VL cases 
are scarce in the literature, and these investigations generally assess cytokine levels 
just once, before any clinical symptoms arise. Research into immune responses shows 
that patients with low levels of IL-10 production have additional flaws. In VL, IL-10 
mRNA expression is highly expressed, and this cytokine’s involvement in reducing T 
cell responses in these individuals has been well established. According to the finding, 
the balance between the production of IFN-γ and IL-10 may be a significant factor 
in determining whether or not patients develop illness after contracting L. chagasi 
infection even while they are asymptomatic [62].
5. Genetics
For many years, there has been speculation that, in VL, the Leishmania geno-
typic differences involve in asymptomatic or symptomatic forms of the disease. 
There was findings that the Leishmania Internal Transcribed Spacer 1 (ITS1) from 
symptomatic VL and asymptomatic cases has significant genetic differences in 
southern Iran [63]. Several investigations have shown that the genotypic char-
acteristics of symptomatic and asymptomatic VL patients might differ [64, 65]. 
Researchers identified significant genetic diversity between Leishmania species iso-
lated from asymptomatic and symptomatic patients, particularly those with HIV/
VL coinfection, in a study done in southern France. The study also discovered that 
asymptomatic isolates had a modest polymorphism in their parasite genome [64]. In 
Southern France, MLMT showed parasite genotype appear to differs in Leishmania 
patients compared with asymptomatic related carriers [66].
Aside from the parasite genotype, the host’s genetic background may have a 
role in determining whether VL is asymptomatic or symptomatic [67]. Study also 
linked symptomatic VL to a gene that codes for a receptor for transforming growth 
factor beta (TGF-β) whereas the asymptomatic is connected to gene encoding II-a 
receptor for the Fc fragment of IgG [67]. However, the association between SNP/
HLA genotyping and progression from asymptomatic or seroconversion to VL overt 
disease has been insignificant [68]. Polymorphism at SLC11A1 has been shown to be 
linked [69, 70] and associated in regulating susceptibility with human VL in Sudan. 
However, no evidence of such an association was found in an Indian population 
[71]. Few studies indicate that host genetic association and development of clinical 
symptoms is linked to NRAMP1, TNF-α, IL-4 and IFN-γ receptor (IFNGR1)], TGF 
β, IL-8, C-X-C chemokine receptor 1 (CXCR1) and C-X-C chemokine receptor 2 
(CXCR2), IL-2R, Delta-like1 (DLL1), and mannan binding lectin genes [48, 69, 72, 
73]. In one of the recent most studies on asymptomatic VL, were able to link several 
HLA-DRβ allele groups with the progression of VL [68].
6. Other risk factors
Besides, serological methodologies performed on individuals without symptoms 
may have low sensitivity due to a weak humoral response [74]. Risk factors have 
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been analyzed by some studies, taking into account that contact with the parasite 
is necessary, but it is not sufficient for the development of the active disease. These 
characteristics can play an important role in the cycle of asymptomatic individuals 
[6]. The male gender is one of the individual factors that demonstrate a positive 
association with asymptomatic infection [75]. Although other hosts and parasite 
variables may be additional causes, the conversion of asymptomatic infections 
to symptomatic VL also indicates the survival of parasites in these people [76]. 
The extrinsic variables such as age and nutritional state, as well as a weakened 
host immunological system, are thought to be significant in the progression from 
asymptomatic to symptomatic infection. Poor dietary status has been linked to 
an increased chance of developing clinical VL in addition to hereditary risk. The 
relationship between malnutrition and the course of VL at the cellular level is 
poorly understood. A better understanding of these mechanisms might open new 
opportunities for prevention or therapeutic dietary intervention [16].
There were evidences that suspected individuals living in households with family 
history, were at particularly high risk of infection. Although the cohort studied did 
not contain population-specific genetic markers, the addition of such factors might 
help predict outcomes when molecular diagnostics and serodiagnostic testing are 
combined. Even if they have a competent immune response, persons who have come 
into touch with the parasite do not inevitably acquire the symptomatic version of 
the condition [16]. Age, genetic, immunological, and dietary features, the existence 
of other diseases, and vector density are all potential risk factors for the disease’s 
development [75], and type of “asymptomatic” definition applied to the study [28]. 
Despite being practical and easy, methodologies handling have some limitations:  
(i) do not differentiate past disease from recent [75, 77] (ii) there is the possibility of 
cross-reactivity with other related parasites [78]. Asymptomatic infection is usually 
observed in family members or in direct contact to clinical VL cases, suggesting that 
family members are at risk of infection. In a research from India, it is discovered 
that family members of VL patients had 1.8 times the risk of becoming infected as 
compared to those who did not have VL in the house. Kala-azar patients were younger 
(P < 0.001) and reported lower red meat consumption (P < 0.01) than asymptomatic 
seropositive individuals. Retinol and zinc levels were lower in current kala-azar 
patients and those who later developed kala-azar compared with uninfected and 
asymptomatically infected subjects. The characteristics that help determine whether 
an infection leads to overt disease appear to include age and dietary factors such 
as intake of iron- and zinc-rich red meat [79, 80]. Kala-azar patients were younger 
(P < 0.001) and reported lower red meat consumption (P < 0.01) than asymptom-
atic seropositive individuals. In comparison to uninfected and asymptomatically 
infected people, active kala-azar patients and those who later acquired kala-azar had 
decreased retinol and zinc levels. In contrast with different groups, kala-azar patients 
had greater CRP values. A population at increased risk of symptomatic illness may 
have a low red meat intake and low zinc and retinol levels.
7. Conclusion
Control efforts for leishmaniasis (especially asymptomatic VL), particularly 
in endemic regions, need a detailed understanding of Leishmania ecology and 
epidemiology. Those infected with viscerotropic Leishmania species, on the other 
hand, may remain asymptomatic, which is the most typical result of infection in 
endemic regions. However, it is impossible to offer reliable estimates of the number 
of infected vs. those at risk. The number of persons infected but asymptomatic is 
far greater than the number of people infected and presenting with clinical disease. 
Leishmania - One of the Most Diverse Anthroponotic Parasitic Diseases
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As a result, it is critical to understand how many infected people will acquire illness 
and how they may be identified before clinical symptoms appear. Different studied 
found that utilizing anti-rK39 ELISA to screen family members and contacts might 
be a very reliable technique for early diagnosis and planning preventive treatment 
of latently infected asymptomatic carriers in order to eradicate kala-azar. Although 
there have been isolated instances of parasite circulation in the peripheral blood 
of asymptomatic individuals with L. donovani and Leishmania tropica infection. 
Various study findings explain the immune response as tracked prospectively and 
its diagnostic value in predicting the fate of latent infection in a relatively large 
number of patients. Serologically positive state a relatively transient increase in 
serum antibodies caused by recent infection that lasts for months, whereas LST 
positive thought to indicate long-term cell-mediated immunity after asymptomatic 
infection or clinical cure of kala-azar. A favorable LST result may take months 
to years to manifest after effective kalaazar therapy, but it lasts for decades after 
exposure. There are few data on risk factors for asymptomatic leishmaniasis, and 
its epidemiology is unknown. Such knowledge is critical for efforts to prevent and 
control visceral leishmaniasis, such as the eradication programs. In a Brazilian 
research, sand flies fed on kala-azar patients were sick in 25% of cases, while none 
of the sand flies fed on asymptomatically afflicted individuals became infected. 
Seroepidemiologic data from disease-endemic areas of India are scarce and based 
on small sample sizes. Serologic status is not a good predictor for conversion to 
clinical VL. Studies confirmed that 33% persons were serologically positive, only 
3.48% seropositive persons showed disease conversion. However, 2.57%seronega-
tive persons at baseline showed disease conversion also [11]. Human instances of 
transfusion-transmitted visceral leishmaniasis (VL) have been reported in both 
endemic and non-endemic locations, with clinical characteristics and outcomes 
comparable to those of natural infection [81].
When innate immune cells from asymptomatic carriers were stimulated with 
antigens in vitro, they exhibited a regulated rise in cytokine production that 
differed from that seen in non-infected subjects. This implies that using more 
than one diagnostic approach makes it easier to identify a substantial proportion 
of asymptomatic carriers. One often mentioned flaw in these research is the dif-
ficulty in identifying those who are briefly and quietly infected with the parasite. 
A recent study of asymptomatic people’ innate and adaptive immunity revealed 
that a mixed cytokine profile is crucial not just for parasite replication control, but 
also for the preservation of these individuals’ immune state [51]. Only 20% of those 
infected with L. chagasi in endemic regions of VL develop classical VL, according 
to research. Even before extremely sensitive molecular diagnostic technologies 
became available, it was established that the majority of infected people living in an 
endemic region have asymptomatic self-cured illnesses [82]. Nonetheless, despite 
the PCR assays’ excellent sensitivity and specificity in identifying Leishmania 
DNA in clinically sick patients’ peripheral blood, a proportion of asymptomatic 
persons with positive serological tests had no detectable circulating Leishmania 
DNA. As a result, the co-positivity between the PCR assay and different serological 
assays was astonishingly low. It’s conceivable that these apparent differences might 
be explained by how an illness develops in people. The parasite can be identified 
in the peripheral blood at a certain point (providing a positive PCR assay), fol-
lowed by adaptive-mediated immunity with the generation of antibodies and a T 
lymphocytes-mediated immune response. Because these biological moments are 
never-ending, it’s possible to analyze certain people when they are in a state of 
transition. Other non-invasive and extremely sensitive techniques, such as PCR in 
peripheral blood, have recently been available. This has made it possible to identify 
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asymptomatic carriers of Leishmnia who otherwise would not have been detected 
using just serological methods [83]. Research findings suggest that the method 
used to diagnose an infection may have an impact on infection-related variables 
including risk factors and treatment results [61]. At the moment, it is impossible 
to determine who among the asymptomatically infected persons will acquire VL 
illness and when. A research from Bangladesh further indicates that about 80% of 
asymptomatic individuals contribute to disease transmission, compared to 8–10% 
of VL and PKDL patients [13].
The question of why just a few exposed asymptomatic people acquire full-
blown illness symptoms but not all remains unsolved. The major immunological 
variables that promote the conversion of asymptomatic patients to symptom-
atic stage of visceral leishmaniasis have been attempted to explicate in several 
research. It is crucial to note that the use of five diagnostic techniques as a regular 
strategy would be impractical in endemic situations. Before a particular recom-
mendation can be made, more research is needed to confirm the optimal diagnos-
tic method [61]. The important checkpoints for determining disease resistance or 
susceptibility are cytokines that control cellular immunity [84, 85]. Despite  
substantial understanding of host–parasite interactions and immunobiology, 
reliable protective immunity criteria have yet to be discovered. Asymptomatic 
instances of human VL can be diagnosed using qPCR using RNA targets. There are 
also questions about whether or not using RNA as a gene target can help discover 
asymptomatic instances of VL. By combining this methodology with epidemio-
logical data analysis, it will be possible to improve the detection and treatment 
of asymptomatic cases. Priority should be given to stepping up efforts to better 
characterize asymptomatic illness in endemic areas and to develop a uniform case 
definition for leishmanial infection. Self-clearing infections vs. illness develop-
ment must have all of their factors examined thoroughly. The problems in parasite 
and sand fly management methods, as well as changes in the epidemiology of VL 
in disease-endemic countries, are important threats to its eradication. In addi-
tion, the movement of infected but asymptomatic people from endemic areas has 
resulted in additional infections in non-endemic areas [86]. The xenodiagnosis 
approach validates whether asymptomatic infected people can be infectious to 
sand flies and might be a crucial step in determining whether or not to modify 
the existing VL management strategy. One study used xenodiagnosis to identify 
VL infection in HIV-positive people and found even asymptomatic patients 
in the early stages of the infection were able to infect others [87]. Although 
Xenodiagnosis findings from an Indian investigation indicate that neither asymp-
tomatic nor treated patients were infected by vector sandflies [88]. Asymptomatic 
infected persons are not now the focus of drug research efforts. This is because the 
asymptomatic state is not clearly defined, but largely because an intervention is 
less of a priority as long as the role of asymptomatically infected people in trans-
mission is not clarified. There have been significant gains in reducing infection 
rates thanks to the eradication programs, but there are still some obstacles to over-
come along the way. Considering that humans are the sole reservoir for Leishmania 
donovani, the effectiveness of a control programme hinges heavily on treating both 
symptomatic and potentially asymptomatic persons, if such individuals are found 
to also function as a reservoir. The lack of techniques to identify live parasites 
in silent infections and their relationship to disease transmission, sterile cure 
characteristics, and PKDL development remains a serious danger to the disease’s 
eradication. There has been tremendous progress in the control or elimination of 
tropical illnesses, with a large drop in the incidence of these diseases. Although it 
is critical to comprehend these underlying causes for each illness, asymptomatic 
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carriers are a common component that can contribute to resurgence; their effect in 
terms of population percentage and function in transmission must be established. 
More study is needed to completely understand the determinants.
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